{"version":1,"type":"story","url":"https://digestai.news/story/pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series","json":"https://digestai.news/story/pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series.json","markdown":"https://digestai.news/story/pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series.md","slug":"pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series","headline":"Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025","summary":"Pathos AI announced on Friday that it closed a $237 million Series E financing, bringing its post‑money valuation to $3 billion, up from $1.6 billion in May 2025, according to Axios via Techmeme.  The round size and valuation reflect strong investor confidence in the company’s approach.\n\nThe biotech leverages artificial intelligence to design oncology drugs, claiming the technology can identify promising molecular candidates faster and optimise clinical‑trial designs.  Management said the new capital will be used to expand its AI platform, advance its pipeline of cancer‑treatment candidates, and scale manufacturing capabilities.\n\nThe latest raise follows earlier funding rounds that have steadily increased the company’s valuation.  Analysts note that the influx of capital into AI‑driven biotech underscores a broader trend of investors betting on machine‑learning‑enhanced drug discovery to accelerate the development of new therapies.","keyPoints":["Pathos AI secured $237 million in a Series E round, bringing post‑money valuation to $3 billion.","Valuation rose from $1.6 billion in May 2025 to $3 billion after the new round.","The biotech uses AI to design oncology drugs and will use funds to expand its platform and pipeline."],"whyItMatters":"The sizable Series E shows investor confidence in AI‑driven drug discovery, potentially accelerating oncology treatments and signaling broader capital flow into biotech platforms that combine machine learning with pharma.","category":{"slug":"business","name":"Business & Funding","url":"https://digestai.news/category/business"},"entities":{"companies":["Pathos AI"],"models":[],"people":["Katherine Davis"]},"firstPublishedAt":"2026-10-23T12:40:01Z","updatedAt":"2026-10-23T12:40:01Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"axios.com","title":"Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025","url":"https://axios.com/pro/biotech-deals/2026/10/23/pathos-ai-raises-237m-3b-valuation","publishedAt":"2026-10-23T12:40:01Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025\", 23 October 2026, https://digestai.news/story/pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series","publisher":"Digest AI","title":"Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025","datePublished":"2026-10-23T12:40:01Z","url":"https://digestai.news/story/pathos-ai-which-uses-ai-to-develop-oncology-drugs-raised-a-237m-series"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}